// App-Quantinova.ai

7528 : Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.

Researchers

Presenter

  • Howland E. Crosswell

Principal Investigators

  • Ann S. LaCasce

  • Nancy L. Bartlett

  • David J. Straus

  • Kerry J. Savage

  • Pier Luigi Zinzani

  • Graham P. Collins

  • Michelle A. Fanale

  • Keenan Fenton

  • Cassie Dong

  • Harry H. Miao

  • Andrew Grigg

Medical Centers

  • Bon Secours Hematology Oncology, Bon Secours, St. Francis Health System, Greenville, SC, Dana-Farber Cancer Institute, Partners CancerCare, Boston, MA

  • Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, BC Cancer, Vancouver, BC, Canada

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Seagen Inc., Bothell, WA, Takeda Oncology, Cambridge, MA

  • Department of Clinical Haematology, Austin Hospital, Melbourne, Australia

Locations

  • Canada

  • Italy

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT01712490

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved